© Copyright khedmeh Wall
The epidermal growth factor receptor (EGFR) is a protein that plays a crucial role in cell growth, division, and survival. It belongs to the ErbB family of receptors, which also includes HER2, HER3, and HER4. EGFR is a transmembrane glycoprotein composed of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain. Its activation triggers a complex signaling network that regulates various cellular processes, including proliferation, differentiation, migration, and apoptosis.
EGFR is normally activated by the binding of specific ligands, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha). This ligand binding induces the formation of EGFR homo- and heterodimers with other ErbB receptors, leading to the autophosphorylation of tyrosine residues in the intracellular domain. These phosphorylated tyrosines serve as docking sites for adapter proteins and enzymes, which initiate several downstream signaling pathways. The most prominent of these pathways are the PI3K/AKT and RAS/RAF/MEK/ERK cascades, which regulate cell survival and proliferation, respectively.
Dysregulation of EGFR activity has been implicated in various human diseases, most notably cancer. Overexpression or mutation of EGFR can lead to its constitutive activation, promoting uncontrolled cell growth and tumorigenesis. This is particularly evident in non-small cell lung cancer (NSCLC), where EGFR mutations are found in approximately 10-15% of patients, especially in East Asian populations. These mutations, often involving exon 19 deletions or the L858R point mutation, confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs) like gefitinib and afatinib.
In addition to NSCLC, EGFR is also overexpressed in other cancers, including breast, colon, head and neck, and pancreatic cancer. Its overexpression often correlates with poor prognosis and resistance to chemotherapy and radiation. Therefore, EGFR has become an attractive target for cancer therapy. Besides TKIs, monoclonal antibodies like cetuximab and panitumumab, which block ligand binding to EGFR, have been approved for the treatment of colorectal cancer and head and neck squamous cell carcinoma.
Creative BioMart, a leading provider of research-grade assay kits, today announced a significant expansion of its product portfolio. The company has introduced hundreds of new kits, bringing its total offerings to over 1,000. This move solidifies Creative BioMart's position as a one-stop-shop for researchers seeking high-quality, ready-to-use kits for a wide array of biological assays.
The newly added kits span multiple categories, including metabolism, epigenetics, cell signaling, and disease biomarker detection. These kits are designed to provide researchers with the tools needed to accurately measure various biological processes and detect specific molecular targets. By offering such a vast array of kits, Creative BioMart aims to support researchers in their efforts to gain a deeper understanding of complex biological systems and develop new treatments for diseases.
"We are thrilled to offer this expanded selection of assay kits to the scientific community," said Linna, the chief marketing staff at Creative BioMart. "Our goal is to support researchers in their quest for knowledge by providing access to a vast array of high-quality, easy-to-use kits that streamline laboratory workflows and accelerate discovery. We believe that by empowering researchers with the right tools, we can help advance scientific knowledge and improve human health."
Creative BioMart's assay kits are known for their exceptional sensitivity, specificity, and reproducibility. Each kit comes with all the necessary reagents, detailed protocols, and analysis tools to ensure researchers can quickly obtain reliable results. The kits are carefully validated to ensure they perform as expected, giving researchers confidence in their findings.
The expanded product line includes kits for detecting a wide range of targets, from enzymes and metabolites to epigenetic marks and signaling proteins. For example, researchers can now find kits for measuring glucose metabolism, detecting specific histone modifications, assessing cellular toxicity, and much more. Whether studying metabolic disorders, cancer, neurodegenerative diseases, or other biological processes, researchers can find the kits they need to advance their research.
"We are committed to continuously innovating and expanding our product offerings to meet the evolving needs of the research community," added Linna. "By providing access to a vast array of high-quality assay kits, we aim to support scientists in their efforts to advance our understanding of biological systems and develop new treatments for diseases. We are dedicated to being a trusted partner for researchers, providing the tools they need to make breakthrough discoveries."
To explore Creative BioMart's newly expanded selection of assay kits, researchers can visit the company's website at https://www.creativebiomart.net/assay-kits.htm.
About Creative BioMart
Creative BioMart provides high-quality research-grade reagents and kits to the life science research community. The company's portfolio includes over 1,000 ready-to-use assay kits, along with a range of recombinant proteins, native proteins, and other research tools.